2023-509158-68-00CompletedPhase 1
First in human study in healthy volunteers and participants with Parkinsons disease with and without GBA1 mutations.
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Jul 2026
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 200 (actual)
- First submitted
- 27 Nov 2023
- Start date
- 25 Jan 2024
- Lead sponsor
- Vanqua Bio Inc.
- Diseases
- Parkinson disease
- EU CT number
- 2023-509158-68-00
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 200
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
Sites (2)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Pharmaceutical Research Associates Group B.V. | Groningen | Netherlands | Completed |
| Centre for Human Drug Research | Leiden | Netherlands | Completed |
The registry text, word for word
This page is information, not medical advice. Discuss any trial with your doctor.